

# Claudia Palladino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6294595/publications.pdf>

Version: 2024-02-01

28  
papers

481  
citations

759233

12  
h-index

677142

22  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. <i>PLoS ONE</i> , 2014, 9, e103345.	2.5	184
2	Impact of Highly Active Antiretroviral Therapy (HAART) on AIDS and Death in a Cohort of Vertically HIV Type 1-Infected Children: 1980â€“2006. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1091-1097.	1.1	26
3	Genetic complexity and gametocyte production of <i>Plasmodium falciparum</i> in Fulani and Mossi communities in Burkina Faso. <i>Parasitology</i> , 2006, 132, 607-14.	1.5	24
4	Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 273-277.	2.0	24
5	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	3.3	22
6	Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. <i>PLoS ONE</i> , 2013, 8, e82718.	2.5	21
7	Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. <i>HIV Medicine</i> , 2011, 12, 442-446.	2.2	20
8	Twin pregnancy as a risk factor for mother-to-child transmission of HIV-1: trends over 20 years. <i>Aids</i> , 2007, 21, 993-1002.	2.2	19
9	HIV-1 Diversity, Transmission Dynamics and Primary Drug Resistance in Angola. <i>PLoS ONE</i> , 2014, 9, e113626.	2.5	17
10	Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 369-376.	3.8	17
11	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. <i>Scientific Reports</i> , 2018, 8, 12266.	3.3	16
12	Causes of Death in Pediatric Patients Vertically Infected by the Human Immunodeficiency Virus Type 1 in Madrid, Spain, From 1982 to Mid-2009. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 495-500.	2.0	14
13	Spatial pattern of HIV-1 mother-to-child-transmission in Madrid (Spain) from 1980 till now: demographic and socioeconomic factors. <i>Aids</i> , 2008, 22, 2199-2205.	2.2	11
14	Short Communication: Evaluation of the Effect of Enfuvirtide in 11 HIV-1 Vertically Infected Pediatric Patients Outside Clinical Trials. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 301-305.	1.1	8
15	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. <i>Scientific Reports</i> , 2017, 7, 2892.	3.3	8
16	Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots. <i>PLoS ONE</i> , 2017, 12, e0181352.	2.5	8
17	LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 563-566.	2.0	8
18	Evaluation of the diagnostic performance of the rapid test VIKIA HIV1/2 in a highly complex HIV-1 epidemic. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 90-92.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012. PLoS ONE, 2014, 9, e96307.	2.5	7
20	ASSOCIATION BETWEEN LIPODYSTROPHY AND LEPTIN IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED CHILDREN RECEIVING LOPINAVIR/RITONAVIR-BASED THERAPY. Pediatric Infectious Disease Journal, 2010, 29, 774-777.	2.0	4
21	Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. Aids, 2015, 29, 2155-2159.	2.2	4
22	Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients. Medicine (United States), 2016, 95, e3842.	1.0	3
23	Frecuencia de sustituciones relevantes asociadas a resistencia en la región NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en España. Enfermedades Infecciosas Y Microbiología Clínica, 2018, 36, 262-267.	0.5	2
24	A Conserved GPG-Motif in the HIV-1 Nef Core Is Required for Principal Nef-Activities. PLoS ONE, 2015, 10, e0145239.	2.5	2
25	Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients. Biomedicines, 2021, 9, 1627.	3.2	2
26	Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance. Journal of Clinical Medicine, 2022, 11, 3579.	2.4	2
27	Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Scientific Reports, 2020, 10, 13024.	3.3	1
28	P-B3â€fEvaluation of an in-house molecular HIV-1 Test to assess Mother-to-Child HIV-1 transmission in Angola (the APEHC cohort). Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 73.	2.1	0